
MILLIMAN RESEARCH REPORT

2024 IFRS 17 disclosure report: Asia

Summary report

September 2025

Julian Man Clement Bonnet Linda Jin Joshua Ho Chong Wen Ang Yu Wei Lim Valensis Justiani Yao Hui Tan





Introduction

For most countries around the world, International Financial Reporting Standard (IFRS) 17 became effective on 1 January 2023. For some Asian insurance markets such as South Korea, Hong Kong, Singapore and Malaysia, the standard also became effective from the same date. In mainland China, the same effective date only applies for companies that are listed overseas and have adopted international accounting standards. For mainland China domestic insurers, the effective date is 1 January 2026. Thailand and Indonesia have implemented IFRS 17 from January 2025, while markets such as the Philippines, India and Taiwan have deferred implementation. Taiwan is set to implement the standard in 2026, and the Philippines and India are expected to follow, with adoption planned for 2027. The timeline for IFRS 17 adoption in Vietnam is uncertain, while Japan has no immediate plans to implement it.

IFRS 17 requires an assessment of the profitability of insurance contracts when they are first issued and, if positive, recognition of profit over the lifetime of the contracts in a manner that reflects the timing of the insurance services provided by the insurer. Specifically, the main features of the new accounting framework for insurance contracts include:

- A fair value measurement of future expected cash flows, incorporating an explicit risk adjustment.
 Assumptions used in the projection need to be the current best estimate.
- A contractual service margin (CSM), which represents the unearned profits of the insurance contract to be recognised in profit and loss (P&L) as service is provided over the coverage period of the insurance contract (any loss is recognised immediately). The CSM is calculated at inception of the contract and then released in a systematic way per group of insurance contracts that best reflects the transfer of services provided under the contract.
 - The CSM cannot be negative (except for reinsurance contracts), so losses from unprofitable contracts are immediately booked in the P&L statements.
- Companies are required to identify contracts that are onerous (loss-making) at inception and group
 them separately from non-onerous contracts. Companies are also required to group contracts written
 one year apart, although exemptions exist in some jurisdictions due to mutualisation effects across
 insurance contracts.
- Compared to the previous IFRS 4 framework (called Phase 1 and implemented in 2014), the presentation of results in the income statement and balance sheet has changed significantly. In particular, the key drivers of profit are shown in the P&L with the presentation of insurance revenue and insurance service expenses in the statement of comprehensive income based on the concept of services provided during the period.

Based on IFRS 17 disclosures of selected insurance companies, we have produced this report giving a comparative analysis of key aspects of the IFRS 17 methodology and financial results. In particular, this report aims to provide inputs to the following questions:

- What are the key commonalities and differences in IFRS 17 methodology among the companies considered in the scope of the analysis?
- How does IFRS 17 impact the adjusted equity as at 31 December 2023 and 31 December 2024, and how does this compare against embedded values?
- What is the impact of IFRS 17 on companies' profitability, including IFRS 17 net profit and non-GAAP operating profit metrics?
- What are the key drivers impacting IFRS 17 profitability, how do they compare across companies, and how have they evolved over time?
- How does new business value creation look under IFRS 17, and how does this compare against a traditional embedded-value new business creation metric as at year-end 2023 and year-end 2024?
- What are the key drivers impacting companies' new business value creation under IFRS 17?

The information contained in the report is based on information publicly disclosed by selected companies as part of their normal disclosure process. Companies included in the analysis are selected global or domestic companies with material business in Asia. For those companies with both life and non-life business, the analysis primarily focuses on their life business. The following companies have been included:

- Multinational companies with material insurance business in Asia (regional companies): AIA Group Limited
 (AIA), FWD Group Holdings Limited (FWD), HSBC Life Insurance (HSBC), Prudential PLC (Prudential), two
 Canadian multinational insurers—namely, Manulife Financial Corporation (Manulife) and Sun Life Financial
 Inc. (Sun Life)—and one European insurer, AXA
- Companies with their main focus on mainland China (China companies): China Pacific Life Insurance Co., Ltd. (CPIC), New China Life Insurance Co., Ltd. (NCI), The People's Insurance Company (Group) of China Limited (PICC), Ping An Life Insurance Company of China, Ltd. (Ping An), and China Taiping Life Insurance (Hong Kong) Company Limited (Taiping)
- Companies operating either in Singapore or in Malaysia (Singapore and Malaysia companies): Allianz Life
 Insurance Malaysia Berhad (Allianz), Maybank Ageas Holdings Berhad (Etiqa), Great Eastern Holdings
 Limited (Great Eastern), Hong Leong Assurance Berhad (Hong Leong; results based on end of June 2024),
 Income Insurance Limited (Income) and Singapore Life Holdings Pte. Ltd. (Singlife)

The report aims to provide initial insights into IFRS 17 financials and the impact on life insurance companies, based on publicly available information and our internal assessment. The observations do not attempt to be exhaustive as we understand that methodologies and results for companies outside this scope may vary significantly. Approximations have been made in some areas, and the results would differ from those presented in this report should a different approach be used. It is also important to recognise that insurance companies have only recently started communicating on the impact of IFRS 17 on their business and, consequently, the information contained in this report is time sensitive and could evolve.

We have produced an executive summary of the full report, which we are sharing here. If you would like to request a copy of the full report or discuss the IFRS 17 disclosure in any of the markets covered in this report in more detail, please contact one of the Milliman consultants listed at the end of the report.

Executive Summary

We have examined IFRS 17 disclosures of year-end 2024 from selected global and domestic insurance companies with substantial operations in Asia, emphasising the underlying methodologies and key financial results, including base case performance and sensitivity disclosures to various risks. It is important to note that our analysis does not aim to provide an exhaustive list of companies. Instead, we have selected representative companies for this study, acknowledging that methodologies and results for companies outside this scope may vary significantly.

In the methodology section, we conduct a comparative analysis based on the disclosed information across different regions and different companies, covering measurement models, risk adjustments, discount rates, coverage units and transition approaches. Although IFRS 17 is largely principle based, allowing companies to develop their own internal calculation methodologies based on their interpretation of the standard, certain similarities and differences are evident among the companies. For instance, there is a consistent application of the variable fee approach (VFA) for participating business and unit-linked products across regions, while both the general measurement model (GMM) and VFA are used for universal life contracts. The value at risk (VaR) approach is commonly employed for calculation of risk adjustments, although the confidence intervals vary among companies. Figures 1 and 2 provide a high-level view of the companies selected across the regions. Overall, while there are consistent trends in certain areas, the underlying methodologies exhibit significant diversity, contributing to variations in results among the companies.

FIGURE 1: EXECUTIVE SUMMARY OF KEY DISCLOSED METHODOLOGY OF SELECTED COMPANIES ACROSS REGIONS

| | REGIONAL | CHINA | SINGAPORE AND MALAYSIA | | |
|---|--|---|------------------------|--|--|
| Measurement Model | Largely consistent for key products, with participating and unit-linked under VFA | | | | |
| Valuation Technique | All use a method similar to typical economic balance sheet calculations | | | | |
| Risk Adjustment | Primarily use VaR, except for two companies that use a margin approach | Mainly use VaR except for two companies that use a cost of capital (CoC) approach | | | |
| Discount Rate | The majority use the bottom-up approach, except for three companies | All use the bottom-up approach | | | |
| Coverage Unit | More information on the insurance services compared to the investment services | | | | |
| Disaggregation of Insurance Finance Expense | Primarily choose the other comprehensive income (OCI) option for certain business lines | | | | |
| Transition Approach | All three approaches are used, but the modified retrospective approach (MRA) is less common among regional companies | | | | |

We have analysed the key results from the IFRS 17 disclosures and compared them to other metrics from supplementary information disclosed by companies, where applicable. The results appear to be region specific, prompting us to compare key selected financials among companies within each region and conduct a regional comparative analysis, which is summarised in Figure 2.

Notable differences in asset classification under IFRS 9 are observed for debt and equity securities with the use of fair value through other comprehensive income (FVOCI) and fair value through profit or loss (FVTPL).

Adjusted equity, defined as the sum of IFRS 17 shareholders' equity and net of tax CSM, is disclosed by regional companies but not by China companies or Singapore and Malaysia companies. While IFRS 17 net profit remains a crucial metric for all, regional companies also use non-GAAP operating profit measures to provide a longer-term perspective on profitability, excluding short-term market fluctuations.

In terms of new business value creation, our analysis of new business CSM (NB CSM) versus traditional embedded value metrics such as value of new business (VNB) indicates no consistent trend among companies or within one geography, as it is driven by valuation basis differences that may vary significantly across different companies or regions.

Our sensitivity analysis indicates that all companies within the scope disclose the impacts of insurance and market risks on P&L and shareholders' equity. However, only regional companies and a few companies from Singapore and Malaysia also report the impacts on the CSM. Among insurance risks, the companies in scope are most sensitive to mortality and morbidity risks, with varying degrees of impact from lapse and expense risks. Regarding market risks, the effects on equity or P&L due to interest rate and equity price fluctuations differ. Additionally, we observe that the P&L impact from market risks can be mitigated by using the OCI option for both assets and liabilities.

FIGURE 2: EXECUTIVE SUMMARY OF KEY DISCLOSED RESULTS AS AT YEAR-END 2024 OF SELECTED COMPANIES ACROSS REGIONS

| | | REGIONAL | CHINA | SINGAPORE AND MALAYSIA |
|---|-----------|--|---|--|
| Asset Classification | Debt | Mainly FVOCI | | Mix of FVOCI and FVTPL |
| | Equity | Mainly FVTPL | | Mix of FVOCI and FVTPL |
| Non-Attributable Expense* to Total Expense | | 9% to 34% | 30% to 43% | 14% to 47% |
| Adjusted Equity* to Embedded Value | | 83% to 122% | 106% to 142% | 87% |
| Profitability | | Stable net profit except one; non-GAAP performance metrics are also disclosed | Relatively stable net profit except one | Relatively stable net profit |
| New Business CSM to VNB | | 84% to 163% | 132% to 500% | 95% to 148% |
| Implied CSM Release Rate* | | 8% to 11% | 8% to 12% | 8% to 14% |
| Discount Rate (implied illiquidity premium) | | USD: 60bps to 85bps HKD: 40bps to 90bps CNY: 30bps to 60bps | Not disclosed | USD: 20bps to 100bps SGD: 25bps to 150bps MYR: 20bps to 100bps |
| Sensitivities | Insurance | Most sensitive to mortality and morbidity risks | | |
| | Market | Company specific and highly affected by risk management practices | | |

^{*} Non-attributable expenses can also relate to other services like fee business or other financial services. Gross of tax CSM is used for the adjusted equity for China companies and Singapore and Malaysia companies since they do not disclose net-of-tax CSM. Implied CSM release rate is defined as CSM release / (NB CSM + Gross CSM BOP).

We hope you find this information useful and would welcome feedback or a conversation about the topics above, and how they may align with your business objective.

Solutions for a world at risk[™]

Milliman leverages deep expertise, actuarial rigor, and advanced technology to develop solutions for a world at risk. We help clients in the public and private sectors navigate urgent, complex challenges—from extreme weather and market volatility to financial insecurity and rising health costs—so they can meet their business, financial, and social objectives. Our solutions encompass insurance, financial services, healthcare, life sciences, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe.

milliman.com



CONTACT

Julian Man julian.man@milliman.com

Clement Bonnet clement.bonnet@milliman.com

Linda Jin linda.jin@milliman.com

Joshua Ho joshua.ho@milliman.com

Chong Wen Ang chongwen.ang@milliman.com

Yu Wei Lim yuwei.lim@milliman.com

Valensis Justiani valensis.justiani@milliman.com

Yao Hui Tan yaohui.tan@milliman.com

© 2025 Milliman, Inc. All Rights Reserved. The materials in this document represent the opinion of the authors and are not representative of the views of Milliman, Inc. Milliman does not certify the information, nor does it guarantee the accuracy and completeness of such information. Use of such information is voluntary and should not be relied upon unless an independent review of its accuracy and completeness has been performed. Materials may not be reproduced without the express consent of Milliman.